The iopamidol industry has entered a period of rapid development, driving the growth of the intermediate serinol market

Serinol, also known as 2-amino-1,3-propanediol, has a molecular formula of C3H9NO2 and a molecular weight of 91.11. It is a prochiral aminoalcohol. Because its structure is similar to serine, it is often called serinol. Serinol is a pharmaceutical intermediate and the main intermediate used to synthesize iopamidol (pharmaceutical name iopamidol).

iopamidol is an Guidelines for Use Second Edition (2013)”, “Chinese Expert Consensus on Cerebral Angiography Operating Standards (2018)”, “American ACR/NKF: Consensus on the Application of Intravenous Iodine Contrast Media in Patients with Kidney Disease (2020)” at home and abroad Authoritative guidelines or expert consensus recommend it for the diagnosis of tumors, cardiovascular and cerebrovascular diseases and other diseases.

The development of the iopamidol industry directly affects the changes in the demand for serinol. China’s pharmaceutical industry continues to develop under the stimulation of policies and market demand growth, especially the development of domestic substitution trends, which has led to an increase in demand for domestic contrast agents. Local iopamidol companies have taken advantage of the trend and industry output has continued to grow, which has become a driving force for China’s serinol demand. It is an important driving force for volume growth and at the same time stimulates local serinol companies to actively increase production to meet market demand. Since 2018, the products of companies such as Stellite and Kelun Pharmaceutical have been registered with the Food and Drug Administration and have been introduced to the market, which has increased the volume of China’s serinol market and thus provided market support for the development of China’s serinol industry.

In the early days, based on good market expectations and corporate development and transformation needs, domestic companies launched serinol production capacity. At present, domestic serinol production capacity can not only meet the growing demand, but also export to markets such as South Korea and India. With the development of China’s iopamidol industry and the increase in production companies, China’s serinol consumption has increased, stimulating the continuous growth of China’s serinol production. According to the“China Serinol Industry Market Monitoring and Future Development Prospects Research Report 2022-2026” released by the Industrial Research Center, In 2021, China’s serinol production was 405.3 tons, the apparent consumption was 332.3 tons, and the export volume was 73.1 tons. Among them, a few API and pharmaceutical intermediate companies such as Xiankang Pharmaceutical and Shengshi Chemical have serinol production capabilities.

Iopamidol is an X-ray non-ionic iodine contrast agent. It has low toxicity to blood vessels and nerves. It has good local and systemic tolerance. It has low osmotic pressure and relatively stable injection solution. It is the best-selling contrast agent in the world. one. Driven by the increasing demand for diagnosis of tumors, cardiovascular diseases, and neurological diseases in China, the scale of the domestic contrast agent market will continue to grow. At the same time, import substitution is also the future development trend of the contrast agent market such as iopamidol. Hokuriku Pharmaceuticals, Sitai Immediately, iopamidol manufacturing companies are actively expanding iopamidol production capacity, which will drive the consumption of serinol in the iopamidol field to increase year by year in the future.